Oncology

Researchers and physicians at Mayo Clinic are collaborating and developing blood tests that detect tumor related material in the blood and may someday be used in place of a biopsy or imaging test to detect and monitor cancer growth.

This week’s Research Roundup highlights immune-mediated autonomic neuropathies following allogeneic stem cell transplantation in acute myeloid leukemia.

This week’s Research Roundup highlights Mayo Clinic researchers who conducted a study to characterize the clinical, pathologic, and survival implications of non-V600 BRAF mutations in metastatic colorectal cancer.

This week’s Research Roundup highlights individual patient-level meta-analysis of the performance of the Decipher genomic classifier in high-risk men after prostatectomy to predict development of metastatic disease.

This week’s Research Roundup highlights how intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation.

In this month’s “Hot Topic,” Alicia Algeciras-Schimnich, Ph.D., will provide you with valuable information regarding the utility of the prostate specific antigen test, and how the calculation of a prostate health index, or phi, can help to stratify a patient’s risk for prostate cancer and reduce unnecessary biopsies.

The prostate health index or phi test reduces the need for prostate cancer biopsies by 30 percent.

This week’s Research Roundup highlights postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease.

This week’s Research Roundup highlights oncologic outcomes for patients with residual cancer at cystectomy following neoadjuvant chemotherapy.

This week’s Research Roundup highlights the evaluation of polygenic risk scores for breast and ovarian cancer risk prediction in BRCA1 and BRCA2 mutation carriers.

This week’s Research Roundup highlights how the androgen receptor variant AR-V9 is co-expressed with AR-V7 in prostate cancer metastases and predicts abiraterone resistance.

Useful For     Video Overview Clinical Information Several PSA isoforms have been identified that can further increase the specificity of PSA for prostate cancer.[...]

Some early-stage cancers are missed by conventional screening and are only detected when symptoms occur. Mayo Clinic is collaborating with Grail, a life science company, and Sutter Health of California, on the STRIVE clinical research study to facilitate the development of Grail’s blood tests for early-stage cancer detection.